Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients

Summary

The aim of this Phase I study is to evaluate the immunogenicity along with safety and toxicity as well as first efficacy of a multi-peptide vaccine adjuvanted with the TLR1/2 ligand XS15 emulsified in Montanide ISA 51 VG (AML-VAC-XS15) in AML patients who have achieved CR or CRi with first line treatment.

Timeline

Start

2024-05-02

Primary completion

2026-05-02

Completion

2026-11-02

Drugs

Indications